ABCL files 8-K: Q3 2025 results press release and presentation

Rhea-AI Filing Summary

AbCellera Biologics Inc. (ABCL) furnished a press release and investor presentation related to its financial and operational results for the quarter ended September 30, 2025. The company aligned the materials with its earnings call on November 6, 2025, and provided them as exhibits.

The information under Items 2.02 and 7.01 is being furnished, not filed, and is not subject to Section 18 liability nor incorporated by reference except as stated. Exhibits include 99.1 (press release) and 99.2 (corporate presentation).

8-K Event Classification

3 items: 2.02, 7.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001703057falseVancouverBC00017030572025-11-062025-11-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

__________________________________________

FORM 8-K

__________________________________________

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 6, 2025

__________________________________________

AbCellera Biologics Inc.

(Exact name of registrant as specified in its charter)

__________________________________________

British Columbia			001-39781			Not Applicable
(State or other jurisdiction of incorporation)			(Commission File Number)			(IRS Employer Identification Number)

150 W 4th Avenue Vancouver, BC			V5Y 1G6
(Address of registrant’s principal executive office)			(Zip code)

(604) 559-9005

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

__________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o						Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o						Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o						Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o						Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading symbol(s)			Name of each exchange on which registered
Common shares			ABCL			The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company  o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o

Item 2.02    Results of Operations and Financial Condition

On November 6, 2025, AbCellera Biologics Inc. (the “Company”), issued a press release announcing its financial and operational results for the quarter ended September 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1.

Item 7.01    Regulation FD Disclosure

In connection with its earnings call on November 6, 2025, to discuss its results for the quarter ended September 30, 2025, the Company will utilize a corporate presentation, a copy of which is furnished herewith as Exhibit 99.2.

The information in Items 2.02 and 7.01 of this Form 8-K (including the exhibits attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing.

Item 9.01    Financial Statements and Exhibits

(d)Exhibits

Exhibit No.						Description
99.1						Press Release issued by AbCellera Biologics Inc. on November 6, 2025.
99.2						Corporate presentation.
104						Cover Page Interactive Data File (embedded as Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 6, 2025			ABCELLERA BIOLOGICS INC.
			By:			/s/ Carl L. G. Hansen
						Carl L. G. Hansen, Ph.D.
						Chief Executive Officer and Director (Principal Executive Officer)

FAQ

What did AbCellera (ABCL) announce in this 8-K?

AbCellera furnished a press release and corporate presentation covering results for the quarter ended September 30, 2025.

Which items of the 8-K are included for AbCellera (ABCL)?

Items 2.02 (Results of Operations and Financial Condition) and 7.01 (Regulation FD Disclosure).

Are the disclosures considered filed or furnished?

They are furnished, not filed, and are not subject to Section 18 liability nor incorporated by reference except as stated.

When was the earnings call referenced by AbCellera (ABCL)?

The earnings call took place on November 6, 2025.

What exhibits were provided with the 8-K?

Exhibit 99.1 is the press release and Exhibit 99.2 is the corporate presentation; 104 is the cover page Inline XBRL.

What period do the results cover for AbCellera (ABCL)?

The results are for the quarter ended September 30, 2025.

Where is AbCellera (ABCL) listed?

AbCellera’s common shares trade on The Nasdaq Stock Market LLC under the symbol ABCL.